Kelly E Dooley

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Am J Trop Med Hyg 80:634-9. 2009
  2. ncbi request reprint Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 58:5245-52. 2014
  3. pmc Treatment Default amongst Patients with Tuberculosis in Urban Morocco: Predicting and Explaining Default and Post-Default Sputum Smear and Drug Susceptibility Results
    Imad Cherkaoui
    Directorate of Epidemiology and Disease Control, Ministry of Health, Rabat, Morocco
    PLoS ONE 9:e93574. 2014
  4. pmc TB and HIV Therapeutics: Pharmacology Research Priorities
    Kelly E Dooley
    Johns Hopkins University School of Medicine, 600 N Wolfe Street, Osler 527, Baltimore, MD 21287, USA
    AIDS Res Treat 2012:874083. 2012
  5. pmc World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 207:1352-8. 2013
  6. doi request reprint Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 62:21-7. 2013
  7. pmc Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 55:572-81. 2012
  8. pmc Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers
    K E Dooley
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Pharmacol Ther 91:881-8. 2012
  9. pmc Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 59:455-62. 2012
  10. pmc T-SPOT.TB responses during treatment of pulmonary tuberculosis
    Samantha Ribeiro
    Instituto de Doenças do Torax Hospital Clementino Fraga Filho Universidade Federal do Rio de Janeiro, Brazil
    BMC Infect Dis 9:23. 2009

Collaborators

Detail Information

Publications18

  1. pmc Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Am J Trop Med Hyg 80:634-9. 2009
    ..51). In conclusion, DM was a risk factor for death in Maryland TB patients. There was a trend toward increased time to culture conversion; two-month culture conversion proportions, however, were similar...
  2. ncbi request reprint Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 58:5245-52. 2014
    ..This study has been registered at ClinicalTrials.gov under registration no. NCT01571414.). ..
  3. pmc Treatment Default amongst Patients with Tuberculosis in Urban Morocco: Predicting and Explaining Default and Post-Default Sputum Smear and Drug Susceptibility Results
    Imad Cherkaoui
    Directorate of Epidemiology and Disease Control, Ministry of Health, Rabat, Morocco
    PLoS ONE 9:e93574. 2014
    ..Public tuberculosis (TB) clinics in urban Morocco...
  4. pmc TB and HIV Therapeutics: Pharmacology Research Priorities
    Kelly E Dooley
    Johns Hopkins University School of Medicine, 600 N Wolfe Street, Osler 527, Baltimore, MD 21287, USA
    AIDS Res Treat 2012:874083. 2012
    ..Priority studies for children and pregnant women with HIV and tuberculosis co-infection are briefly discussed...
  5. pmc World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 207:1352-8. 2013
    ..Although World Health Organization group 5 drugs are not recommended for routine use because of unclear activity, some may have untapped potential as more efficacious or better tolerated alternatives...
  6. doi request reprint Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 62:21-7. 2013
    ..This study evaluated the effect of RIF or rifabutin (RBT) on the pharmacokinetics of the investigational HIV integrase inhibitor, dolutegravir (DTG)...
  7. pmc Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 55:572-81. 2012
    ..Further research focusing on optimization of dose and duration of drugs with activity against drug-resistant tuberculosis is paramount...
  8. pmc Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers
    K E Dooley
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Pharmacol Ther 91:881-8. 2012
    ..01).Changes in the oral clearance of MDZ did not vary by RP T dose. In conclusion, RP T was tolerated at doses as high as20 mg/kg/day, its PK were less than dose-proportional, and its CYP 3A induction was robust...
  9. pmc Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 59:455-62. 2012
    ..Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral drug efavirenz...
  10. pmc T-SPOT.TB responses during treatment of pulmonary tuberculosis
    Samantha Ribeiro
    Instituto de Doenças do Torax Hospital Clementino Fraga Filho Universidade Federal do Rio de Janeiro, Brazil
    BMC Infect Dis 9:23. 2009
    ..Immune responses to Mycobacterium tuberculosis antigens could serve as surrogate markers of treatment response...
  11. pmc Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, USA
    BMC Public Health 11:140. 2011
    ..We also assessed retreatment outcomes and drug susceptibility testing use for retreatment patients in urban centers in Morocco, where tuberculosis incidence is stubbornly high...
  12. ncbi request reprint Fluoroquinolone resistance in patients with newly diagnosed tuberculosis
    Amy Sarah Ginsburg
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 37:1448-52. 2003
    ..The incidence of M. tuberculosis fluoroquinolone resistance in this small sample of patients with newly diagnosed tuberculosis was high, particularly among patients with prior fluoroquinolone exposure...
  13. pmc Tuberculosis and diabetes mellitus: convergence of two epidemics
    Kelly E Dooley
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Lancet Infect Dis 9:737-46. 2009
    ..In addition, we review potential mechanisms by which diabetes mellitus can cause tuberculosis, the effects of tuberculosis on diabetic control, and pharmacokinetic issues related to the co-management of diabetes and tuberculosis...
  14. ncbi request reprint Pipeline of drugs for related diseases: tuberculosis
    Kelly E Dooley
    aJohns Hopkins University School of Medicine, Baltimore, Maryland, USA bStellenbosch University, Tygerberg, South Africa
    Curr Opin HIV AIDS 8:579-85. 2013
    ..In this review, the results of recent trials evaluating novel combination regimens for TB disease and latent TB infection are described...
  15. doi request reprint Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries
    Kelly E Dooley
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 198:948-61. 2008
  16. ncbi request reprint Treatment of latent tuberculosis infection: challenges and prospects
    Kelly E Dooley
    Department of Medicine, Providence Portland Medical Center, 4805 NE Glissan Street, Portland, OR 97213, USA
    Clin Chest Med 26:313-26, vii. 2005
    ..This article reviews the treatment of latent tuberculosis infection in HIV-seropositive and HIV-seronegative persons...
  17. pmc Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice
    Deepak Almeida
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS Negl Trop Dis 5:e933. 2011
    ..We tested two entirely oral regimens for BU treatment, rifampin(RIF)+clarithromycin(CLR) and rifapentine(RPT)+clarithromycin(CLR) in the mouse model...
  18. ncbi request reprint Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis
    Kelly E Dooley
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 34:1607-12. 2002
    ..04). Initial empiric therapy with a fluoroquinolone was associated with a delay in the initiation of appropriate antituberculosis treatment...